InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financial-statements
TL;DR
InMed Pharma filed an 8-K, likely financial updates. No major news yet.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on April 18, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the reporting of these items.
Why It Matters
This 8-K filing indicates that InMed Pharmaceuticals Inc. is providing updates or disclosures required by the SEC, which could include financial information or other material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative or positive material events.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer of the 8-K report
- April 18, 2024 (date) — Date of the earliest event reported
FAQ
What is the primary purpose of this 8-K filing by InMed Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 18, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
What is the SIC code for InMed Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for InMed Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-18 13:30:26
Filing Documents
- ea0204175-8k_inmed.htm (8-K) — 36KB
- ea020417501ex99-1_inmed.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-034053.txt ( ) — 276KB
- inm-20240418.xsd (EX-101.SCH) — 3KB
- inm-20240418_def.xml (EX-101.DEF) — 26KB
- inm-20240418_lab.xml (EX-101.LAB) — 33KB
- inm-20240418_pre.xml (EX-101.PRE) — 22KB
- ea0204175-8k_inmed_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated April 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: April 18, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2